Suppr超能文献

经导管主动脉瓣置换术后合并心房颤动的患者中维生素 K 拮抗剂与直接口服抗凝剂的疗效和安全性比较:系统评价和荟萃分析。

Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis.

机构信息

The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.

出版信息

Clin Cardiol. 2022 Oct;45(10):1002-1010. doi: 10.1002/clc.23909. Epub 2022 Aug 28.

Abstract

In the past decade, direct oral anticoagulants (DOACs) have proven to be the best option for patients with nonvalvular atrial fibrillation. Nevertheless, evidence for the use of DOACs for anticoagulation in valvular atrial fibrillation, particularly after aortic valve replacement, remains inadequate. Thus, we conducted a meta-analysis to compare the efficacy and safety of vitamin K antagonists (VKAs) and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement (TAVR). We conducted a comprehensive search of online databases, and 11 studies were included in the final analysis. The primary endpoint was all-cause mortality. Secondary endpoints included stroke and cardiovascular death. The safe endpoint is major and/or life-threatening bleeding. Subgroup analysis was conducted according to the different follow-up time of each study. Random-effects models were used for all outcomes. Statistical heterogeneity was assessed using χ tests and quantified using I  statistics. Patients in the DOACs group had a significantly lower risk of all-cause mortality compared with patients in the VKAs group (relative risk [RR]: 1.20, 95% confidence interval [CI]: 1.01-1.43, p = .04). This benefit may be greater with longer follow-up. In a subgroup analysis based on the length of follow-up, a significantly lower risk of all-cause mortality was found in the DOACs group in the subgroup with a follow-up time of >12 months (RR: 1.50, 95% CI: 1.07-2.09, p = .001). There were no significant differences between the two groups in cardiovascular death, stroke, and major and/or life-threatening bleeding. For patients with atrial fibrillation after TAVR, the use of DOACs may be superior to VKAs, and the benefit may be greater with longer follow-up. The anticoagulant strategy for atrial fibrillation after TAVR is a valuable direction for future research.

摘要

在过去的十年中,直接口服抗凝剂(DOACs)已被证明是治疗非瓣膜性心房颤动患者的最佳选择。然而,DOACs 在瓣膜性心房颤动(尤其是主动脉瓣置换术后)中的抗凝作用证据仍然不足。因此,我们进行了一项荟萃分析,以比较维生素 K 拮抗剂(VKAs)和 DOACs 在经导管主动脉瓣置换术(TAVR)后心房颤动患者中的疗效和安全性。我们全面检索了在线数据库,最终有 11 项研究纳入了分析。主要终点是全因死亡率。次要终点包括卒中和心血管死亡。安全性终点是大出血的主要和/或危及生命。根据每个研究的不同随访时间进行了亚组分析。所有结果均采用随机效应模型进行分析。采用 χ 检验评估统计异质性,并采用 I ² 统计量量化。与 VKAs 组相比,DOACs 组患者的全因死亡率风险显著降低(相对风险 [RR]:1.20,95%置信区间 [CI]:1.01-1.43,p=0.04)。这种益处可能随着随访时间的延长而增加。在基于随访时间的亚组分析中,在随访时间>12 个月的亚组中,DOACs 组的全因死亡率风险显著降低(RR:1.50,95%CI:1.07-2.09,p=0.001)。两组间在心血管死亡、卒中和大出血的主要和/或危及生命方面无显著差异。对于 TAVR 后患有心房颤动的患者,使用 DOACs 可能优于 VKAs,并且随着随访时间的延长,益处可能更大。TAVR 后心房颤动的抗凝策略是未来研究的一个有价值的方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f50/9574758/9e1021dbd4fc/CLC-45-1002-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验